FYI:
Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo (p < 0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059).
- Forums
- ASX - By Stock
- XJO
- Thursday, 30 April - An Apetite for Risk
Thursday, 30 April - An Apetite for Risk, page-6
-
- There are more pages in this discussion • 149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add XJO (ASX) to my watchlist
(20min delay)
|
|||||
Last
8,099.9 |
Change
24.200(0.30%) |
Mkt cap ! n/a |
Open | High | Low |
8,075.7 | 8,143.6 | 8,075.7 |
Featured News
XJO (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online